Cancer Therapeutics Crc Pty Limited

Ctxt Pty Limited

Danny Ganame

Richard Charles Foitzik

Romina Lessene

Ian Peter Holmes

Catherine Fae Hemley

Scott Raymond Walker

Gillian Elizabeth Lunniss

Neil Choi

Paul Anthony Stupple

Michelle Ang Camerino

Ylva Elisabet Bergman

Benjamin Joseph Morrow

Marica Nikac

Andrew John Harvey

Wilhelmus Johannes Antonius Kersten

Yiva Bergman

H Rachel Lagiakos

John Feutrill

Gillian Elizabeth Lunnis

Marcia Nikac

Neil Chol

A compound of formula (1a), (1b) or (1c) wherein: n is 1 or 2; Ris H or Me; Ris optionally one or more halo or methyl groups; Rand Rare independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CHOH; Rand R(if present) are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CHOH; Rand Rare independently selected from H and Me; Ris selected from OH, &#x2014;NH, &#x2014;C(&#x2550;O)NH, and &#x2014;CHOH; Ris either H or Me; Ris either H or Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted Cheteroaryl. 

Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors

A compound of the formula (I): where Ror Ris a cyclic amine group and Ris an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.

FAK inhibitors

This invention relates to compounds of the formula (I): The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer, as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphangiogenesis.

VEGFR3 inhibitors

This invention relates to a compound of the formula (I):  The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer, as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphangiogenesis.

A compound of the formula (I): where Ror Ris a cycle, amine group and Ris an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.

Selective FAK inhibitors

A compound of the formula (I): where Ror Ris a cyclc amine group and Ris an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.

Growing community of inventors

Bundoora, Australia

Danny Ganame